Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisinin + piperazine is a hypothetical or non-standard combination of two distinct antiparasitic agents. Artemisinin is a sesquiterpene lactone derived from the plant *Artemisia annua* and is widely used as an antimalarial, particularly in artemisinin-based combination therapies (ACTs). Its mechanism involves generating reactive oxygen species that damage malarial parasites, primarily by interacting with heme iron within the parasite, leading to inhibition of protein and nucleic acid synthesis[6][10]. Piperazine is an anthelmintic agent used to treat intestinal worm infections such as ascariasis (roundworm) and enterobiasis (pinworm), acting by paralyzing worms so they can be expelled from the body[8]. There are no known approved pharmaceutical products or clinical evidence supporting the use of this specific combination for any indication. Each drug has distinct mechanisms and indications—artemisinin for malaria, piperazine for helminth infections—and they are not typically co-formulated or co-administered.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisinin + piperazine.